Becker’s Healthcare Podcast How Health Systems Are Reshaping Clinical Decision-Making by Turning Molecular Data into Actionable Care
Dec 18, 2025
In this engaging discussion, Solomon Moshkevich, President of Clinical Diagnostics at Natera, delves into the power of molecular data in reshaping healthcare. He highlights how MRD testing and AI tools are revolutionizing clinical decisions in oncology and chronic kidney disease. Solomon shares insights on the innovative Signatera test for personalized care and addresses the challenges of integrating precision tools within health systems. He also discusses the promising future of early cancer screening and how genetics can transform chronic kidney disease management.
AI Snips
Chapters
Transcript
Episode notes
MRD Changes How Oncology Decisions Are Made
- MRD testing reveals microscopic cancer that scans can miss and changes treatment decisions.
- Personalized Signatera assays detect recurrence earlier with high specificity across cancer types.
Build Evidence Then Integrate With AI
- Generate robust clinical evidence before integrating new diagnostics into care.
- Build EMR-integrated, AI-driven clinical decision support to identify eligible patients and measure outcomes.
MRD-Guided Care Improves Survival And Reduces Overtreatment
- MRD-guided adjuvant therapy can both improve survival and spare many patients from unnecessary treatment.
- In muscle-invasive bladder cancer, MRD-directed care improved overall survival by over 40% in a recent NEJM study.